FHTX250117P10000
- 0.00
- 0.000.00%
Foghorn Therapeutics Newsroom
H.C. Wainwright Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Cuts Target Price to $13
Morgan Stanley Maintains Foghorn Therapeutics(FHTX.US) With Hold Rating, Maintains Target Price $9
Foghorn Therapeutics: Hold Rating Amid Strategic Pivot and Uncertainty in Drug Development
12 Health Care Stocks Moving In Monday's Pre-Market Session
Foghorn Therapeutics Is Maintained at Buy by Jefferies
Foghorn Therapeutics Analyst Ratings
Wedbush Cuts Price Target on Foghorn Therapeutics to $10 From $13, Keeps Outperform Rating
Why Foghorn Therapeutics (FHTX) Stock Is Trading Lower
Jefferies Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Cuts Target Price to $14
Sector Update: Health Care Stocks Mixed Pre-Bell Monday
Express News | Foghorn Therapeutics Inc. : Jefferies Cuts Target Price to $14 From $18
Foghorn Therapeutics Ends Solo Development of FHD-286
Express News | Foghorn Therapeutics Shares Down 37.2% Premarket After Co Halts Independent Development of Cancer Treatment
Foghorn Therapeutics Advances Precision Oncology Pipeline
Trading Halt: Halt Status Updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times
Express News | Foghorn Therapeutics Inc. - Phase 1 Trial of Fhd-286 Showed Clinical Responses but Did Not Meet Threshold
Express News | Foghorn Therapeutics Inc. - to Discontinue Independent Development of Fhd-286 for Aml
Express News | Foghorn Therapeutics Provides Update on Fhd-286 Clinical Development Program and Strategic Priorities
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
Trading Halt: Halted at 6:55:00 A.m. ET - Trading Halt: Halt News Pending